Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 6/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | USP19 | O94966 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320352 | 0.82 | FEN1 (0.49) | PDK2TGFBR1MAP4K4GABRA1GABRG2 | |
| SCHEMBL320160 | 0.81 | MET (0.47) | TGFBR1MAP4K4GABRA1GABRG2GABRB3 | |
| SCHEMBL320460 | 0.73 | TGFBR1 (0.48) | PDK2TGFBR1MAP4K4GABRA1GABRG2 | |
| SCHEMBL10153189 | 0.72 | MET (0.49) | PDK2TGFBR1MAP4K4GABRA1GABRG2 | |
| SCHEMBL320854 | 0.71 | TGFBR1 (0.59) | TGFBR1MAP4K4FEN1 | |
| SCHEMBL320657 | 0.71 | TGFBR1 (0.51) | PDK2TGFBR1MAP4K4FEN1 | |
| SCHEMBL320493 | 0.71 | TGFBR1 (0.46) | PDK2TGFBR1MAP4K4GABRA1GABRG2 | |
| SCHEMBL14877229 | 0.70 | MAPK1 (0.45) | TGFBR1MAP4K4MAPK1FEN1 | |
| SCHEMBL320368 | 0.68 | TGFBR1 (0.49) | TGFBR1MAP4K4GABRA1GABRG2GABRB3 | |
| SCHEMBL2325458 | 0.66 | FEN1 (0.47) | PDK2TGFBR1RORCFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | PDK2 560/4885TGFBR1 1/4885MAP4K4 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.